Senator Dick Durbin, D-Illinois, said that the “termination cliff” on the transition date creates a “perverse incentive that could delay approval” for biosimilar insulins, and said that the new legislation would create a faster approval path for lower-cost products.
The Biologics Price Competition and Innovation Act (BPCIA) states that biologics that were originally approved through New Drug Applications (NDAs) under the Federal Food, Drug, and Cosmetic Act—such as insulins—will be deemed to be licensed as biologic products under the Public Health Service Act at the end of a 10-year transition period that closes on March 23, 2020.
As part of that transition, according to the FDA’s final guidance on the matter, any NDAs for transition products that are pending a decision on March 20, 2020 will receive Complete Responses. The FDA has indicated that these applications will have to be resubmitted via pathways for novel biologics or for biosimilars.
However, there has been concern that this approach by the FDA will lead to a “regulatory dead zone” in which insulin products will see delayed approval.
This month, a new item of legislation was introduced to address that potential problem. S.2103, or the Affordable Insulin Approvals Now Act, would amend the BPCIA to require that insulins with filing dates not later than December 31, 2019, would continue to be reviewed and approved under section 505 of the Food, Drug and Cosmetic Act, even if the review and approval process were to continue past the March transition date. These drugs would be deemed to be licensed as biologics effective on either the transition date or the date of approval, whichever comes later.
The bill was introduced by Senators Dick Durbin, D-Illinois, Kevin Cramer, R-North Dakota, and Tina Smith, D-Minnesota. In a statement, Durbin said that the “termination cliff” on the transition date creates a “perverse incentive that could delay approval” for biosimilar insulins, and said that the legislation would create a faster approval path for lower-cost products.
The legislation has received support from the Diabetes Patient Advocacy Coalition, the National Diabetes Volunteer Leadership Council, and Children with Diabetes.
This bill is part of a spate of action from law makers indented to address the problem of skyrocketing insulin costs. Also introduced this month was another bill targeting insulin: the Insulin Price Reduction Act. The bill would prohibit pharmacy benefit managers (PBMs) and insurers from receiving rebates for insulin if the drug maker has lowered its 2020 list prices to 2006 levels. To retain the rebate restriction in the next year, increases in the insulin’s list price must not exceed inflation. The rebate restrictions would apply to all private insurance plans and Medicare Part D plans.
In addition, the bill would require that PBMs and insurers waive the deductible for private insurance plans for any insulin that meets the list price reduction requirements each year.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).